1. Home
  2. KREF vs PRTC Comparison

KREF vs PRTC Comparison

Compare KREF & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Real Estate Finance Trust Inc.

KREF

KKR Real Estate Finance Trust Inc.

N/A

Current Price

$7.22

Market Cap

416.7M

Sector

Real Estate

ML Signal

N/A

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$17.42

Market Cap

423.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KREF
PRTC
Founded
2014
2015
Country
United States
United States
Employees
N/A
56
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.7M
423.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KREF
PRTC
Price
$7.22
$17.42
Analyst Decision
Hold
Analyst Count
6
0
Target Price
$7.88
N/A
AVG Volume (30 Days)
883.3K
4.8K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
6.49%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$545.92
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$14.50
52 Week High
$9.98
$19.92

Technical Indicators

Market Signals
Indicator
KREF
PRTC
Relative Strength Index (RSI) 68.41 51.72
Support Level $6.64 $16.67
Resistance Level $7.50 $18.70
Average True Range (ATR) 0.16 0.76
MACD 0.05 -0.04
Stochastic Oscillator 78.40 30.55

Price Performance

Historical Comparison
KREF
PRTC

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: